Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease

Gang Liu; Ping Men; Wataru Kudo; George Perry; Mark A. Smith

doi:10.1016/j.neulet.2009.03.064

Related publications

Article2009

Development of iron chelator–nanoparticle conjugates as potential therapeutic agents for Alzheimer disease

Gang Liu, Ping Men, George Perry, Mark A. Smith

Article2009

Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β

Rudy J. Castellani, Hyoung‐gon Lee, Sandra L. Siedlak, Akihiko Nunomura, Takaaki Hayashi, Masao Nakamura, Xiongwei Zhu, George Perry, Mark A. Smith

Article2005

Role of Amyloid‐β in Alzheimer's Disease

Mark A. Smith, George Perry

Article2009

Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease

Nikolaos Tezapsidis, Jane M. Johnston, Mark A. Smith, J. Wesson Ashford, Gemma Casadesús, Nikolaos K. Robakis, Benjamin Wolozin, George Perry, Xiongwei Zhu, Steven J. Greco, Sraboni Sarkar

Article2017

Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer’s Disease

Anne Tristan, Lizmar Carreño, Mario Quijada, Vu T. Nguyen, George Perry, Oleg V. Larionov, Ricardo Lleonart, Patricia L. Fernández, Deborah Doens, Pedro A. Valiente, Adelphe M. Mfuh, Anh X. T. Vo

Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease

Discussion(0)

Related publications

Development of iron chelator–nanoparticle conjugates as potential therapeutic agents for Alzheimer disease

Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β

Role of Amyloid‐β in Alzheimer's Disease

Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease

Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer’s Disease